Adding a low-dose antihypertensive regimen would substantially improve the control of hypertension and reduce cardiovascular morbidity among uncomplicated hypertensive patients
Restricted accessResearch articleFirst published online August, 2012
Adding a low-dose antihypertensive regimen would substantially improve the control of hypertension and reduce cardiovascular morbidity among uncomplicated hypertensive patients
Aims: To assess the utilization of antihypertensive drugs among uncomplicated hypertensive patients in Finland between 2000 and 2006 and to calculate the achievable reduction in cardiovascular morbidity, with intensified antihypertensive treatment. Methods: From the databases of the Social Insurance Institution of Finland, 428,986 treated hypertensives without diabetes or cardiac disease (further named uncomplicated hypertensives) in 2000 and 591,206 in 2006, respectively, were identified. In addition, from the Health 2000 survey representing the whole Finnish adult population, 729 uncomplicated hypertensives were determined to assess their characteristics and control of hypertension. Applying Law′s meta-analyses we calculated the reduction of blood pressure (BP) by intensifying the treatment with low-dose antihypertensive regimens for those with a BP ≥140/90 mmHg. Results: The nationwide data suggests a relative overuse of beta-blockers. Combination antihypertensive treatment increased relatively 8%, while at least three drug combinations increased from 19.8% to 21.6% between 2000 and 2006. However, calculated prevalence of controlled BP (<140/90 mmHg) increased only from 30.3% to 33.9%. Addition of one half standard dose or one to two half standard doses for the treatment of the patients with a BP ≥140/90 mmHg would improve the control of hypertension from 33.9% to 47.8% and 67.3%, respectively. The intensified treatment would reduce strokes by 18% and 28%, and ischaemic heart disease events by 13% and 21%, respectively. Conclusions: Underutilization of preferred drugs and poor control of BP continues. Surprisingly small addition of the number of low-dose antihypertensive regimen is needed in order to substantially improve the control of hypertension and to decrease cardiovascular morbidity among uncomplicated hypertensive patients.
CollinsRPetoRMacMahonSHebertPFiebachNHEberleinKA. Blood pressure, stroke, and coronary heart disease. Part 2. Short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet1990; 335(8693): 827–838.
2.
LawMRMorrisJKWaldNJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ2009; 338(7705): b1665–b1665.
3.
LawesCMRodgersABennettDAParagVSuhIUeshimaH. Blood pressure and cardiovascular disease in the Asia Pacific region. J Hypertens2003; 21(4): 707–716.
4.
LawesCMBennettDAFeiginVLRodgersA. Blood pressure and stroke: an overview of published reviews. Stroke2004; 35(4): 1024–1024.
5.
WilliamsBLacyPSThomSMCruickshankKStantonACollierD. Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study. Circulation2006; 113(9): 1213–1225.
6.
LawMRWaldNJMorrisJKJordanRE. Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials. BMJ2003; 326(7404): 1427–1427.
7.
ManciaGLaurentSAgabiti-RoseiEAmbrosioniEBurnierMCaulfieldMJ. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J Hypertens2009; 27(11): 2121–2158.
8.
WaldDSLawMMorrisJKBestwickJPWaldNJ. Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11,000 participants from 42 trials. Am J Med2009; 122(3): 290–300.
9.
ManciaGZanchettiA. Choice of antihypertensive drugs in the European Society of Hypertension-European Society of Cardiology guidelines: specific indications rather than ranking for general usage. J Hypertens2008; 26(2): 164–168.
10.
KastarinenMAntikainenRPeltonenMLaatikainenTBarengoNCJulaA. Prevalence, awareness and treatment of hypertension in Finland during 1982⊟2007. J Hypertens2009; 27(8): 1552–1559.
11.
Danon-HerschNMarques-VidalPBovetPChioleroAPaccaudFPecoudA. Prevalence, awareness, treatment and control of high blood pressure in a Swiss city general population: the CoLaus study. Eur J Cardiovasc Prev Rehabil2009; 16(1): 66–72.
12.
KearneyPMWheltonMReynoldsKWheltonPKHeJ. Worldwide prevalence of hypertension: a systematic review. J Hypertens2004; 22(1): 11–19.
13.
PereiraMLunetNAzevedoABarrosH. Differences in prevalence, awareness, treatment and control of hypertension between developing and developed countries. J Hypertens2009; 27(5): 963–975.
14.
AholaTLJulaAMKantolaIMMakiJKlaukkaTReunanenA. Positive change in the utilization of antihypertensive and lipid-lowering drugs among adult diabetics in Finland. Results from large national database between 2000 and 2006. J Hypertens2009; 27(11): 2283–2293.
15.
AholaTLKantolaIMPuukkaPKattainenAKlaukkaTReunanenA. Positive change in the utilization of antihypertensive and lipid-lowering drugs among adult CHD patients in Finland: results from a large national database between 2000 and 2006. Eur J Cardiovasc Prev Rehabil2010; 17(4): 477–485.
16.
KoskinenSAromaaA. Health and functional capacity in Finland. Baseline results of the Health 2000 Health Examination Survey. Helsinki: National Public Health Institute. http://www.ktl.fi/terveys2000/julkaisut/baseline.pdf (January 2009).
17.
DahlofBDevereuxRBKjeldsenSEJuliusSBeeversGde FaireU. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet2002; 359(9311): 995–1003.
18.
WilliamsBPoulterNRBrownMJDavisMMcInnesGTPotterJF. British Hypertension Society guidelines for hypertension management 2004 (BHS-IV): summary. BMJ2004; 328(7440): 634–640.
19.
Agabiti RoseiERizzoniD. Metabolic profile of nebivolol, a beta-adrenoceptor antagonist with unique characteristics. Drugs2007; 67(8): 1097–1107.
20.
GalderisiMD’ErricoASidiropulosMInnelliPde DivitiisOde SimoneG. Nebivolol induces parallel improvement of left ventricular filling pressure and coronary flow reserve in uncomplicated arterial hypertension. J Hypertens2009; 27(10): 2108–2115.
21.
LindholmLHCarlbergBSamuelssonO. Should beta blockers remain first choice in the treatment of primary hypertension? A meta-analysis. Lancet2005; 366(9496): 1545–1553.
22.
OpieLH. Beta-blockade should not be among several choices for initial therapy of hypertension. J Hypertens2008; 26(2): 161–163.
23.
MesserliFHBangaloreSJuliusS. Risk/benefit assessment of beta-blockers and diuretics precludes their use for first-line therapy in hypertension. Circulation2008; 117(20): 2706–2715(discussion 2715).
24.
KhanNMcAlisterFA. Re-examining the efficacy of beta-blockers for the treatment of hypertension: a meta-analysis. CMAJ2006; 174(12): 1737–1742.
25.
ElliottWJMeyerPM. Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. Lancet2007; 369(9557): 201–207.
26.
ManciaGGrassiGZanchettiA. New-onset diabetes and antihypertensive drugs. J Hypertens2006; 24(1): 3–10.
27.
BangaloreSParkarSGrossmanEMesserliFH. A meta-analysis of 94,492 patients with hypertension treated with beta blockers to determine the risk of new-onset diabetes mellitus. Am J Cardiol2007; 100(8): 1254–1262.
28.
ManolisADoumasM. Sexual dysfunction: the ‘prima ballerina’ of hypertension-related quality-of-life complications. J Hypertens2008; 26(11): 2074–2084.
29.
SeverPSDahlofBPoulterNRWedelHBeeversGCaulfieldM. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial − Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet2003; 361(9364): 1149–1158.
